The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome
Overview
The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors
Full Title of Study: “The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: December 2022
Interventions
- Drug: methylphenidate, fluoxetin, risperidone
- first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
Arms, Groups and Cohorts
- Experimental: 1
Clinical Trial Outcome Measures
Primary Measures
- Measure that are used: psychological measures, molecular tests, responsiveness to medical treatments
- Time Frame: 2 years
Participating in This Clinical Trial
Inclusion Criteria
- chromosomal deletion proven by FISH examination Exclusion Criteria:
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- The Chaim Sheba Medical Center
- Provider of Information About this Clinical Study
- Principal Investigator: Prof. Doron Gothelf, Principal Investigator – The Chaim Sheba Medical Center
- Overall Contact(s)
- Doron Gothelf, MD, 972-03-5302663, gothelf@post.tau.ac.il
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.